Qiagen (NYSE:QGEN) Hits New 52-Week High at $47.17

Qiagen (NYSE:QGEN) shares reached a new 52-week high on Wednesday . The company traded as high as $47.17 and last traded at $47.08, with a volume of 270810 shares changing hands. The stock had previously closed at $46.97.

Analysts Set New Price Targets

QGEN has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. upped their price objective on shares of Qiagen from $52.00 to $54.00 and gave the stock an “overweight” rating in a research report on Tuesday, June 18th. Stifel Nicolaus decreased their price target on Qiagen from $55.00 to $45.00 and set a “hold” rating for the company in a research report on Wednesday, May 1st. Wolfe Research raised Qiagen from a “peer perform” rating to an “outperform” rating and set a $50.00 price objective on the stock in a research report on Thursday, June 27th. Finally, Robert W. Baird raised their target price on Qiagen from $49.00 to $52.00 and gave the company an “outperform” rating in a research report on Friday, August 2nd. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $51.10.

Qiagen Price Performance

The company has a current ratio of 1.77, a quick ratio of 1.46 and a debt-to-equity ratio of 0.27. The stock has a market cap of $10.74 billion, a PE ratio of 31.50, a PEG ratio of 3.28 and a beta of 0.40. The business has a 50-day moving average price of $43.11 and a 200 day moving average price of $43.11.

Qiagen (NYSE:QGEN) last announced its quarterly earnings data on Wednesday, July 31st. The company reported $0.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.52 by $0.03. The business had revenue of $496.00 million for the quarter, compared to analysts’ expectations of $495.45 million. Qiagen had a return on equity of 12.92% and a net margin of 3.75%. The firm’s quarterly revenue was down .2% compared to the same quarter last year. During the same period in the previous year, the business posted $0.53 EPS. As a group, research analysts forecast that Qiagen will post 2.15 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of QGEN. Quarry LP lifted its position in shares of Qiagen by 152.0% during the second quarter. Quarry LP now owns 4,146 shares of the company’s stock worth $170,000 after acquiring an additional 2,501 shares in the last quarter. Creative Planning lifted its holdings in Qiagen by 6.2% during the 2nd quarter. Creative Planning now owns 36,010 shares of the company’s stock worth $1,480,000 after purchasing an additional 2,115 shares in the last quarter. Susquehanna International Securities Ltd. lifted its holdings in Qiagen by 9.8% during the 2nd quarter. Susquehanna International Securities Ltd. now owns 146,337 shares of the company’s stock worth $6,013,000 after purchasing an additional 13,026 shares in the last quarter. Susquehanna Fundamental Investments LLC boosted its stake in Qiagen by 235.5% in the 2nd quarter. Susquehanna Fundamental Investments LLC now owns 77,557 shares of the company’s stock worth $3,187,000 after purchasing an additional 54,439 shares during the period. Finally, Mackenzie Financial Corp grew its holdings in Qiagen by 8.1% during the 2nd quarter. Mackenzie Financial Corp now owns 424,685 shares of the company’s stock valued at $17,539,000 after buying an additional 31,758 shares in the last quarter. 70.00% of the stock is owned by institutional investors.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.